Forkhead box protein E1 (FOXE1)

Forkhead box protein E1 (FOXE1) is a nuclear transcription factor of the FOX family, characterized by a winged-helix DNA binding domain that enables pioneer activity—remodeling chromatin and facilitating the binding of other transcriptional regulators[2][4][1]. FOXE1 acts primarily in thyroid development, supporting precursor cell migration, differentiation repression, and maintenance of hormone-producing capacity in adulthood[2][4]. Mutations or altered expression of FOXE1 are associated with syndromic congenital hypothyroidism featuring cleft palate and other developmental anomalies, as well as susceptibility to thyroid and other cancers[2][3][4][1]. Functionally, FOXE1 directly binds to regulatory DNA motifs in thyroglobulin (TG), thyroperoxidase (TPO), and other thyroid-specific genes, often in collaboration with factors such as ELK1 (ETS family) and NF1/CTF[1][2]. Natural and experimentally-induced changes in the FOXE1 polyalanine tract modulate transcriptional output, influencing disease risk and severity[3][1].\n\nNo clinically approved drugs directly target FOXE1, but mechanistic studies show that pathway inhibitors (e.g., MEK inhibitors) can disrupt FOXE1-driven transcriptional programs in thyroid cells[1]. Variants, especially in the polyalanine tract, serve as biomarkers of disease risk and may inform future therapeutic strategies[3][4][1]. FOXE1's essential developmental functions and role in cancer make it an important research and diagnostic target.

Other names

Thyroid transcription factor 2 (TTF-2)FKHL15FOXE2HFKL5HFKH4Forkhead box protein E2Forkhead-related protein FKHL15HNF-3/fork head-like protein 5Bamforth–Lazarus syndrome proteinNMTC4TITF2TTF-2

For experimental inhibitors, inhibition of FOXE1's transcriptional network or disruption of its interaction with ETS-family transcription factor ELK1